| Company / Ticker | Forward P/E | Price-to-Sales (P/S) | Dividend Yield | Payout Ratio | | :--- | :--- | :--- | :--- | :--- | | Bristol-Myers Squibb (BMY) | ~9.3x - 13.4x | 2.6x | 4.10% - 4.22% | ~39.0% - 55.4% | | Pfizer (PFE) | 9.9x | ~2.7x | 5.82% | 226.3% (GAAP) | | Novo Nordisk (NVO) | 11.2x - 11.8x | N/A (Premium) | 4.63% | 44.8% |
(Data derived from recent consensus estimates [cite: 4, 5, 6, 7, 8, 9, 10, 11, 12]. Note: Payout ratios can skew dramatically due to one-time GAAP charges, as seen with PFE's inflated metric).
Multiples and Peer Comparison
Forward P/E Ratio: As of late 2026, BMY is trading at a depressed Forward Price-to-Earnings ratio of approximately 9.0x to 9.5x (GuruFocus). This represents a stark roughly 37% discount to the Drug Manufacturers industry median of 14.75x. Trailing P/E Ratio: On a trailing twelve-month basis, the P/E sits at roughly 13.4x to 13.9x. For context, BMY's historical 10-year average P/E ratio is roughly 36x, and its 5-year median is 17.9x, indicating the stock is trading vastly below its historical norms (FullRatio). Price-to-Sales (P/S): The stock trades at a highly attractive 2.6x to 2.7x forward sales multiple [cite: 10]. When compared to peers like Novo Nordisk (trading at over 12.6x forward earnings and 3.3x sales), BMY appears to be a deep-value play within the healthcare sector (Motley Fool).
Fair Value Synthesis
Because BMY's future earnings are expected to follow a non-linear trajectory (steady growth through 2027, followed by a sharp contraction in 2028-2030, followed by a hopeful pipeline-driven recovery), standard trailing multiples are insufficient for valuation. Discounted Cash Flow (DCF) models present a wide variance based on terminal growth assumptions.
A two-stage EPS-based DCF model by A.L. Capital Advisory generated a blended base-case fair value of $93 per share, with a bear case of $62 and a bull case of $123. At current trading levels near $60, this implies a potential margin of safety of over +35% to base fair value (AL Capital Advisory). Conversely, proprietary algorithms like the GF Value metric estimate a fair value of only $56.81, asserting the stock is modestly overvalued due to the forecasted free cash flow contraction in the coming years (GuruFocus).
The core takeaway is that BMY is definitively cheap relative to current earnings. The market is betting that the earnings denominator (the "E" in the P/E ratio) will collapse in 2028. If BMY's Growth Portfolio can offset even a fraction of the expected patent cliff losses, the current sub-10x forward multiple represents a significant mispricing and an opportunity for multiple expansion.
Risks, Red Flags, and The 2028 Patent Cliff
To understand BMY's suppressed valuation, one must explode the narrative surrounding the 2028 Loss of Exclusivity (LOE) cliff. This is not a standard patent expiration cycle; it is an existential threat to the company's core revenue foundation.
The Twin Pillars: Eliquis and Opdivo
In 2025, BMY generated total corporate revenues of $48.2 billion. Of that total, two drugs were responsible for more than half: 1. Eliquis (apixaban): An oral anticoagulant co-marketed with Pfizer, which brought in $14.4 billion for BMY. 2. Opdivo (nivolumab): A cornerstone cancer immunotherapy biologic, generating $10.0 billion.
Together, these two assets constitute 50.8% ($24.5 billion) of BMY's total revenue (Drug Patent Watch). Both drugs are slated to face US generic or biosimilar competition in 2028.
The Eliquis Threat (Small Molecule): Eliquis is a small-molecule drug, meaning it will face traditional generic competition. When small-molecule drugs lose exclusivity, pharmacy-level substitution laws typically result in a devastating revenue collapse—often a 70% to 90% loss of market share within the first 12 months. The generic entry date for Eliquis in the US is locked via court settlement for April 1, 2028 (Credevo). Furthermore, Eliquis was targeted under the Inflation Reduction Act (IRA), with Medicare-negotiated maximum fair pricing taking effect on January 1, 2026. The Centers for Medicare and Medicaid Services (CMS) has imposed a maximum fair price of $231.00 for a 30-day equivalent supply of Eliquis, representing a steep 56% discount from its $521.00 list price [cite: 13]. This severe mandated markdown means revenue erosion will begin years before the actual patent expires (Motley Fool).
The Opdivo Threat (Biologic): Opdivo is a biologic, meaning it will face "biosimilar" competition. Historically, biosimilar erosion has been slower than small-molecule generics due to manufacturing complexities and physician reluctance to switch stable cancer patients. However, the regulatory environment is streamlining. BMY is currently embroiled in litigation with Amgen to prevent the early launch of an Opdivo copycat, but the structural reality remains that Opdivo sales will suffer a terminal decline beginning in 2028 (Seeking Alpha).
Legacy Portfolio Erosion Already Underway
The 2028 cliff is exacerbated by ongoing erosion elsewhere in the legacy portfolio. The multiple myeloma drug Revlimid, once the crown jewel of the Celgene acquisition, lost exclusivity in 2022 and has been in managed decline through staggered generic entry agreements. Additionally, Pomalyst (another multiple myeloma therapy) began facing severe generic competition in Europe in 2024, driving worldwide sales down from $3.55 billion to $2.73 billion in a single year, with US generic entry expected imminently in 2026 (FiercePharma).
The compounding effect of Revlimid, Pomalyst, Eliquis, and Opdivo losing exclusivity creates a revenue void that is nearly unprecedented in modern biopharma history.
